Wearable Devices Faciliate the Management of AMI Patients

Recruiting

• Conditions: Acute Myocardial Infarction

• Registration Number: NCT06995495
• Lead Sponsor: RenJi Hospital

Brief Summary

The study will explore the use of wearable technology to consistently monitor patients with acute myocardial infarction (AMI) receiving primary percutaneous coronary intervention (PCI). Parameters such as heart rate, sleep time, physical activity, and blood pressure will be collected and analyzed to characterize the patients and predict clinical outcomes.

Detailed Description

The aim of this study is to explore in-hospital patient management and predict clinical outcomes in AMI patients receiving primary PCI through wearable technology (e.g., smart watches and wristband devices). The investigators expect to involve patients diagnosed with AMI, including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI), who are admitted to the cardiac Cardiac Intensive Care Unit (CICU) after primary PCI.

With written consent, eligible participants will be consistently monitored by a wearable device during the CICU stay, in addition to a conventional monitoring system. Vital signs including heart rate (beats/minute), oxygen saturation (%) blood pressure (mmHg), and other crucial parameters such as sleep patterns will be recorded. The collected data will be analyzed using AI-assisted and machine learning techniques, integrated with other clinical data to construct models that support risk stratification, guide clinical decision-making, improve the quality of nursing care, and predict long-term prognosis for these patients. Serial follow-ups (6-month, annual, and long-term) will be performed, and important information such as cardiac function assessed by echocardiography, the incidence of major adverse cardiovascular events, and life qualities will be collected for each follow-up.

Study Timeline

• Study Start: 2024-04-01
• Study First Submitted: 2025-01-21
• Status Verified: 2025-05
• Study First Submitted QC: 2025-05-20
• Last Update Submitted: 2025-05-20
• Study First Posted: 2025-05-29
• Last Update Posted: 2025-05-29
• Primary Completion: 2025-07-01
• Study Completion: 2025-10-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• Aged 18-75 years old
• Diagnosed with STEMI or NSTEMI (ACC/AHA guidelines)
• Half male and half female
• Undergo CAG and PCI treatment;
• Written informed consent.

Exclusion Criteria

• People under the age of 18 years old;
• Patients who are pregnant/breastfeeding;
• Patients who are allergic to the metallic or plastic components of the wearable devices

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Heart Rate Pattern assessed artificial intelligence (AI)-assisted analysis	Throughout the full course of hospitalization, with an average of 1 week.	The dynamic trajectory or trend of a patient's heart rate measurements over the course of hospital stay. Time series data will be analyzed by AI-assisted machine learning model.

Secondary Outcome Measures

Name	Time	Method
The event rate of coronary revascularization	From date of enrollment until the date of follow-ups at 1-month, 6-month and 1-year post discharge.	The proportion (%) of participants who undergo an unplanned coronary revascularization procedure-either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
Cardiac function assessed by echocardiography	At 1-month, 6-month and 1-year follow-ups.	Cadiac function is evaluated as left ventricular ejection fraction (LVEF, %) by echocardiography
The event rate of heart failure	From date of enrollment until the date of follow-ups at 1-month, 6-month and 1-year post discharge.	The proportion (%) of participants who experience symptomatic heart failure. Heart failure is diagnosed based on symptoms such as shortness of breath and excess fluid, in the presence of a reduced LVEF (\<60%) as assessed by echocardiography.
The event rate of re-infarction	From date of enrollment until the date of follow-ups at 1-month, 6-month and 1-year post discharge.	The proportion (%) of participants who experience recurrent myocardial infarction, refers to a new or additional heart attack that occurs after the myocardial infarction diagnosed at enrollment.
Cardiovascular mortality (%)	From date of enrollment until date of death from cardiovascular causes, or assessed up to 12 months.	Cardiovascular mortality (%) is defined as the proportion of participants who die due to cardiovascular causes during the follow-up period. Cardiovascular causes include myocardial infarction, heart failure, stroke, sudden cardiac death, or other documented cardiac or vascular events.

Trial Locations

Locations (1)

Renji Hospital; 🇨🇳 Shanghai, China